Development of anti-cancer drug modified by the peptide binding to cholangiocarcinoma.
| Project/Area Number |
20591588
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Shinshu University |
|---|
Principal Investigator |
ISHIZONE Satoshi Shinshu University, 医学部附属病院, 助教 (90419341)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIYAGAWA Shinichi 信州大学, 医学部, 教授 (80229806)
KOMATSU Daisuke 信州大学, 医学部附属病院, 助教 (50507481)
MURANAKA Futoshi 信州大学, 医学部附属病院, 医員 (80507492)
|
|---|
| Research Collaborator |
SHIMIZU Akira 信州大学, 医学部附属病院, 助教 (00447773)
KITAHARA Hiroe 信州大学, 医学部附属病院, 医員 (20569321)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2009: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2008: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | バイオパンニング法 / 消化器癌標的治療 / ペプチド / バイオパニング法 |
|---|
| Research Abstract |
Cholangiocarcinoma (CCA) is a common carcinoma of the liver, and the majority of patients with CCA have a poor prognosis due to the lack of effective non-surgical therapies in addition to its rapid progression and inoperability at the time of diagnosis. The development of novel non-surgical therapeutics that efficiently target CCA could significantly improve the prognosis for patients presenting with CCA. Here, we describe the iteration and characterization of a novel peptide, designated COP35 (CCA-binding oligo-peptide #35) that binds selectively to human CCA identified by bacteriophage biopanning using the intrahepatic cholangiocarcinoma cell line RBE and the normal cholangiocyte cell line MMNK-1. COP35 was found to augment the growth inhibitory effects of 5-FU against RBE cells. Utilizing pull down assay and liquid chromatography, we identify the clathrin heavy chain (CHC) accompanied by GRP78/BiP as a COP35 binding partner. In summary, we identify COP35 as a possible candidate for peptide targeted therapies for CCA.
|
Report
(4 results)
Research Products
(25 results)
-
[Journal Article] CoP35, a cholangiocarcinoma-binding oligo-peptide, interacts with the clathrin heavy chain accompanied by GRP78.2011
Author(s)
Kitahara H, Masumoto J, Parker AL, Maruta F, Kubo N, Shimizu A, Akita N, Miwa S, Kobayashi N, Nakayama J, Miyagawa S.
-
Journal Title
Related Report
Peer Reviewed
-
-
-
-
-
[Journal Article] Antiproinflammatory effects of iodixanol (OptiPrep)-based density gradient purification on human islet preparations.2010
Author(s)
Mita A, Ricordi C, Messinger S, Miki A, Misawa R, Barker S, Molano RD, Haertter R, Khan A, Miyagawa S, Pileggi A, Inverardi L, Alejandro R, Hering BJ, Ichii H.
-
Journal Title
Cell Transplant. 19(12)
Pages: 1537-1546
Related Report
Peer Reviewed
-
-
-
[Journal Article] Adrenomedullin in sinusoidal endothelial cells play protective roles against cold injury of liver.2010
Author(s)
Iinuma N, Sakurai T, Kamiyoshi A, Ichikawa-Shindo Y, Arai T, Yoshizawa T, Koyama T, Uetake R, Kawate H, Muto S, Tagawa Y, Miyagawa S, Shindo T.
-
Journal Title
Peptides. 31(5)
Pages: 865-871
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
